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Abstract
N-acetylaspartate (NAA) is an amino acid derivative primarily located in the neurons of the adult brain. The function of
NAA is incompletely understood. Decrease in brain tissue NAA is presently considered symptomatic and a potential
biomarker of acute and chronic neuropathological conditions. The aim of this study was to use microdialysis to investigate
the behavior of extracellular NAA (eNAA) levels after traumatic brain injury (TBI). Sampling for this study was
performed using cerebral microdialysis catheters (M Dialysis 71) perfused at 0.3 lL/min. Extracellular NAA was mea-
sured in microdialysates by high-performance liquid chromatography in 30 patients with severe TBI and for comparison,
in radiographically ‘‘normal’’ areas of brain in six non-TBI neurosurgical patients. We established a detailed temporal
eNAA profile in eight of the severe TBI patients. Microdialysate concentrations of glucose, lactate, pyruvate, glutamate,
and glycerol were measured on an ISCUS clinical microdialysis analyzer. Here, we show that the temporal profile of
microdialysate eNAA was characterized by highest levels in the earliest time-points post-injury, followed by a steady
decline; beyond 70 h post-injury, average levels were 40% lower than those measured in non-TBI patients. There was a
significant inverse correlation between concentrations of eNAA and pyruvate; eNAA showed significant positive corre-
lations with glycerol and the lactate/pyruvate (L/P) ratio measured in microdialysates. The results of this on-going study
suggest that changes in eNAA after TBI relate to the release of intracellular components, possibly due to neuronal death or
injury, as well as to adverse brain energy metabolism.
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Introduction
N-acetylaspartate (NAA) is one of the most abundant aminoacid derivatives present in the central nervous system (CNS),
where it is thought to play a significant functional role.1 NAA was
first reported in 1956, though its function, complex synthesis, and
metabolism remain poorly understood.2 NAA is synthesized in the
neuronal cytosol from acetic acid and L-aspartic acid by the endo-
plasmic reticulum-associated enzyme N-acetyltransferase 8-like.3–6
Upon release, NAA is taken up by oligodendrocytes for hydrolysis
to acetic acid and L-aspartic acid via the enzyme aspartoacylase
(ASPA).7 Input by astrocytes is required for ASPA to catalyze
this reaction.8 NAA biosynthesis and processing is thus linked to
the availability of acetyl coenzyme A (acetyl-CoA), cell adenosine
triphosphate (ATP) stores, overall energy state, and mitochondrial
phosphorylating capacity.9
The role of NAA in myelin lipid synthesis, particularly in early
development, is well established. The acetic acid from NAA
becomes incorporated into CNS myelin.10 Inherited ASPA gene
mutations result in Canavan disease, showing ASPA deficiency
in oligodendrocytes, abnormally high brain NAA levels, defi-
cient axonal myelin sheath development, and spongy degenera-
tion of white matter.11–14 NAA plays a vital role as a precursor for
the neurotransmitter N-acetylaspartylglutamate.15 In addition,
NAA traps excess aspartate and thus transports amino group
nitrogen from mitochondria to the cytoplasm.16,17 NAA may
provide a store of energy metabolism precursors in neurons, as-
trocytes and oligodendrocytes in the absence of a sufficient store
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of glycogen,3 and may be involved in maintaining neuronal os-
molytic balance.1,18,19
In proton magnetic resonance spectroscopy (1H-MRS) of brain,
NAA shows as a large, prominent peak. Relative to healthy con-
trols, NAA is significantly reduced in neurological conditions, such
as stroke, Alzheimer’s disease, dementia, Huntington’s disease,
multiple sclerosis, and epilepsy.20,21 Although mechanisms remain
unclear, diminished NAA is considered a non-invasive 1H-MRS
marker for neuronal injury, morbidity, or metabolic dysfunc-
tion.22,23 Severe traumatic brain injury (TBI) results in a reduction
in the brain NAA levels (measured ex vivo by high-performance
liquid chromatography [HPLC]) in animal models, even in areas
remote from the focal injury.6 This reduction recovered to basal
level in diffuse neuronal injury models at a rate inversely propor-
tional to injury severity and in correlation with brain energy state.6
Partial recovery of brain NAA levels was reported using 1H-MRS
in a small follow-up study of acute brain damage patients.24
Microdialysis (MD) is a well-established technique enabling
both clinical monitoring at the bedside and neurochemical analysis
in the laboratory, for extracellular molecules from the human
brain.25,26 Extracellular NAA (eNAA) levels in rats with diffuse
TBI did not differ significantly from sham baseline in brain mi-
crodialysates and whole brain tissue, and in brain 1H-MRS.27,28
Recently, TBI patients with microdialysis were studied by Belli and
colleagues., who reported that a lower average eNAA concentra-
tion in the 9 d following injury was associated with poorer clinical
outcome, whereas a peak in eNAA at around 5 d post-injury was
associated with patient survival.23 In the present study, we have
measured eNAA in 30 TBI patients with microdialysis. We have
analyzed the detailed temporal profile of eNAA concentrations in
eight of these TBI patients, along with other biochemical markers.
We have compared eNAA levels in TBI patients who received
glucose-supplemented microdialysis fluid and those who did not to
establish the cellular response to a localized improvement in fuel
supply. We also have compared TBI eNAA levels with those from
‘‘normal’’ brain in six non-TBI neurosurgical patients.
Methods
Subjects
The study was approved by the Cambridge Local Research
Ethics Committee and assent obtained from the next of kin. All TBI
subjects were patients in the Neurosciences Critical Care Unit
(NCCU) in Addenbrooke’s Hospital, Cambridge. Patients were
older than 16 years of age with TBI requiring ventilation and in-
tracranial pressure (ICP) monitoring. The major exclusion criterion
was deranged clotting and/or low platelets, precluding the place-
ment of a microdialysis catheter. None of the TBI patients had any
significant previous neurological conditions or a family history of
neuro-degenerative disease.
Patients undergoing a craniotomy for resection of benign brain
tumors, enabling microdialysis catheters to be safely placed into
radiographically normal brain, were selected as control subjects.
The microdialysis catheters were placed via the craniotomy and
tunneled under the scalp of the patient. Control patients were awake
for the duration of the microdialysis perfusion.
Microdialysis
A total of 30 TBI patients were monitored using microdialysis,
which was started as soon as possible following admission to the
NCCU. Microdialysis catheters (CMA71, 100 kDa molecular
weight cut-off respectively, 10-mm membrane; M Dialysis AB,
Stockholm, Sweden) were inserted into the cerebral frontal pa-
renchyma of patients, together with an ICP transducer (Codman,
Raynham, MA) using a triple-lumen cranial access device (Tech-
nicam, Newton Abbot, UK). One of the 30 patients studied received
two catheters at different cranial sites. The catheters were perfused
with either regular CNS perfusion fluid (NaCl, 147 mM; KCl,
2.7 mM; CaCl2, 1.2 mM; and MgCl2, 0.85 mM in water; M Dialysis
AB), or CNS perfusion fluid supplemented with 4 mM 1,2-13C2
glucose (Pharmacy Manufacturing Unit, the Ipswich Hospital NHS
Trust, Ipswich, UK). Patients with two catheters were treated with
two types of perfusion fluid: one with and one without glucose
supplementation. A perfusion flow rate of 0.3 lL min-1 was pro-
vided using a CMA106 pump (M Dialysis AB). Collection vials
were changed hourly and analyzed at the bedside for glucose,
lactate, pyruvate and glutamate or glycerol, using a CMA600 or
ISCUSFlex microdialysis analyzer (M Dialysis AB) using auto-
mated enzymatic colorimetric assays as part of routine multi-
modality monitoring. Microdialysates were then stored at
-80C for subsequent analysis by HPLC to determine amino acids
and NAA. Microdialysates from each patient were pooled into ei-
ther 8 h periods (normal CNS perfusion fluid) or 24 h periods (CNS
perfusion fluid supplemented with glucose) for HPLC analysis.
The six benign tumor resection patients were monitored using
microdialysis, which commenced immediately after surgery was
completed. The catheters were perfused with CNS perfusion fluid
(as above) supplemented with glucose (as above) at a flow rate of
0.3 lL min-1. Collection vials were changed hourly and analyzed
with the ISCUS at 4-h intervals. Microdialysates were then stored at
-80C for subsequent analysis by HPLC to determine amino acids
and NAA. Microdialysates from each patient were pooled into 24 h
periods for HPLC analysis.
Determination of N-acetylaspartate (NAA) by HPLC
Microdialysate samples were diluted using the ratio of 5lL of
microdialysate with 10 lL of water prior to HPLC analysis on an
Agilent 1100 series HPLC (Agilent Technologies, Waldbronn,
Germany) using an adapted version of methodology published
previously.29 The HPLC system comprised of a binary pump, re-
frigerated auto-sampler (at 10C), and ultraviolet detector (at
210 nm), with a ChemStation data system (Agilent). The column
(maintained at 20C) was a Phenomenex Hyperclone C18
(150 mm· 2 mm, particle size 3lm, pore size 100 A˚; Phenomenex,
Torrance, CA), with a Phenomenex SecurityGuard Luna C18(2)
guard cartridge. The mobile phase (0.25 mL min-1) was continu-
ously vacuum-degassed. Using the auto-sampler, each pre-diluted
microdialysate sample (2 lL) was injected onto the HPLC column.
Separation was achieved using isocratic elution. Mobile phase
consisted of 25 mM potassium phosphate in water, 2.8 mM tetra-
butylammonium hydroxide (Sigma-Aldrich, Gillingham, Dorset,
UK), and 1.25% v/v methanol, pH 7.0. The run time was 15 min,
and after every four samples, the column was washed with a mobile
phase consisting of 100 mM potassium phosphate in water, 2.8 mM
tetrabutylammonium hydroxide, and 30% v/v methanol, pH 5.5.
Before injection of the next four samples, the column was equili-
brated with the original mobile phase for 1 h. Quantitation was by
peak areas relative to external standards of NAA (Sigma-Aldrich).
NAA typically eluted at 6.6 mins. The limit of quantification of the
HPLC method is 1.8 lM.
Statistical analysis
Statistical analyses were performed using SPSS21 software
(IBM SPSS Statistics, Armonk, NY) included non-parametric tests
(Mann-Whitney U-test). Relationships between eNAA and time
after injury or operation, and eNAA and other biomarkers were
explored using linear regression, with Spearman’s rank correlation
coefficient r and analysis of variance (ANOVA) p values. A pre-
selected p value of 0.05 was considered statistically significant.
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Results
Demography
A total of 30 severe TBI patients and six non-TBI patients were
studied. Extracellular NAA concentrations were monitored in a
detailed temporal profile in eight of the TBI patients (five male and
three female), ages 20 to 69 years (median, 56 years). Extracellular
NAA was also measured in 22 additional severe TBI patients (17
male and five female), ages 16 to 64 years (median, 28 years). The
latter group of patients received either non-supplemented perfusion
fluid, or 4 mM 1,2-13C2 glucose-supplemented perfusion fluid via
the microdialysis catheter, while simultaneously collecting the
emerging microdialysates for analysis. One of the 22 patients re-
ceived two microdialysis catheters at different locations, through
Table 1. Patient Demography and Types of Perfusion Fluid
TBI Time-course
Patient Age Sex
Injury
mechanism
GCS at
scene/15
Microdialysis
start time
after injury / h GOS score
Perfusion fluid -
1,2 -13C2 glucose
concentration
1 27 M Fall 8 48 3 0
2 28 M RTC 3 24 2 0
3 29 M RTC 4 72 3 0
4 30 F RTC 3 48 3 0
5 31 F RTC 14 24 3 0
6 32 F RTC 12 35 3 0
7 33 M Assault 9 20 5 0
8 34 M Fall 11 18 3 0
TBI
patient Age Sex
Injury
mechanism
GCS at
scene/15
Microdialysis
start time
after injury / h GOS score
Perfusion fluid -
1,2 -13C2 glucose
concentration
Number of
sampling
periods
9 26 F RTC 6 17 4 4 mM 2
10 27 M RTC 7 45 5 4 mM 2
11 53 F RTC 6 41 3 4 mM 2
12 59 F RTC 4 60 3 4 mM 2
13 16 F RTC 4 47 5 4 mM 2
14 37 M RTC 8 49 5 4 mM 1
15 28 M RTC 3 104 5 4 mM 2
16 20 M RTC 4 132 4 4 mM 1
17 20 M RTC 5 51 NA 4 mM 1
18 25 M RTC 8 26 4 4 mM 1
19 20 M RTC 4 88 5 4 mM 1
20 (A) 27 M Assault 5 17 3 4 mM 1
20 (B) Unsupplemented 1
21 61 M RTC 11 27 4 Unsupplemented 1
22 49 M Assault NA 41 4 Unsupplemented 1
23 47 M Fall 7 65 4 4 mM 4
24 27 M Fall NA 17 3 Unsupplemented 1
25 27 M RTC NA 27 N/A 4 mM 3
26 28 F Fall 11 104 3 4 mM 1
27 29 M RTC NA 16 3 4 mM 1
28 52 M Fall 8 15 5 4 mM 1
29 64 M Fall NA 98 1 4 mM 1
30 49 M Fall 3 20 2 4 mM 1
Normal brain
subject Age Sex
Benign tumor
type
Perfusion fluid -
1,2 -13C2 glucose
concentration
Number of
sampling
periods
1 60 F Meningioma 4 mM 1
2 59 M Colloid cyst 4 mM 2
3 59 M Meningioma 4 mM 1
4 73 M Meningioma 4 mM 2
5 50 F Meningioma 4 mM 1
6 42 F Meningioma 4 mM 1
A total of 30 TBI patients and non-TBI neurosurgical patients were recruited. Twenty-two TBI patients underwent a period of microdialysis with either
unsupplemented perfusion fluid, or perfusion fluid containing 4 mM 1,2-13C2 glucose. Another eight patients who received unsupplemented perfusion
fluid were monitored for eNAA over a period of £240 h. Six non-TBI patients undergoing craniotomies for benign tumors underwent microdialysis with
the catheter placed in radiographically normal brain, all of whom received perfusion fluid supplemented with 4 mM 1,2-13C2 glucose.
TBI, traumatic brain injury; GCS, Glasgow Coma Scale score; GOS, Glasgow Outcome Scale; M, male; RTC, road traffic collision; F, female.
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which the concentration of glucose also varied. Radiographically
normal–appearing brain was studied as a means of comparison
using the aforementioned 13C-labeled microdialysis method in six
patients (ages 42–73 years; three male, three female) undergoing
surgery for benign brain tumors. The 22 additional TBI patients,
and the six normal brain control patients were the same patients
reported in a previous study within our research group.30 Patient
demography and the types of perfusion fluid for each patient are
presented in Table 1.
Temporal profile of eNAA concentration
The time-course of eNAA concentration was determined in eight
patients for an average monitoring period ranging from 36 h to 75 h
after injury, the exact times of which are shown in Figure 1. The
average time monitored in each patient was 39 h, and the average
time for every data-point was 8 h. Figure 2 shows the average
eNAA concentration for each data-point for the eight patients
monitored, plotted versus post-injury time. A steep decline in the
concentration of eNAA occurred early after injury, particularly in
Patients 1, 2, and 7, where monitoring began <50 h rather than later
after injury (Fig. 2). Taking together the data from all eight patients,
there was a significant inverse correlation between eNAA con-
centration and time post-injury (Fig. 2). A significant difference
also was observed between eNAA concentrations before and after
96 h post-injury (Mann-Whitney, p = 0.017). None of the patients
who took part in this study died as a result of their injuries; how-
ever, it was noted that the highest concentration of eNAA was
obtained in the first sample taken after injury (Fig. 2) from the
patient with the worst clinical outcome (Glasgow Outcome Scale
[GOS] score 2).
Effect of glucose supplementation
through microdialysis catheter
The effect of localized fuel (glucose) supplementation via the
microdialysis catheter on the eNAA concentration was deter-
mined in 22 TBI patients. Of these, four were treated with non-
supplemented perfusion fluid, and the remaining 17 were treated
with perfusion fluid containing 4 mM glucose. The concentrations
of eNAA plotted versus time post-injury are shown in Figure 3,
where the data-points are differentiated according to the compo-
sition of the perfusion fluid. A significant inverse relationship be-
tween time post-injury and eNAA concentration was observed for
FIG. 1. Time lines for sampling and analysis of microdialysis
samples from eight traumatic brain injury patients during the time-
course study. MD, microdialysis; NAA, N-acetylaspartate. Color
image is available online at www.liebertpub.com/neu
FIG. 2. The temporal profile of extracellular N-acetylaspartate (eNAA) concentration in microdialysis samples from eight traumatic
brain injury patients in relation to time since injury. Each data-point represents one 8 h pooled sample. Results are for n = 61 data-points,
Spearman r= -0.28, p= 0.032. Color image is available online at www.liebertpub.com/neu
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patients receiving microdialysis with perfusion fluid supplemented
with 4 mM glucose (Fig. 3).
Microdialysis of non-TBI patients
with glucose supplementation
Extracellular NAA concentrations were measured in radio-
graphically normal areas of brain in six patients who underwent
surgery for benign brain tumors as non-TBI controls for compari-
son with eNAA data from TBI patients. All six non-TBI patients
received perfusion fluid supplemented with 4 mM glucose through
the MD catheter. The eNAA concentrations obtained from the non-
TBI patients in relation to time since operation are shown alongside
the eNAA levels measured in TBI patients in Figure 3. No signif-
icant correlation was found between time post-operation and eNAA
concentration for non-TBI patients (n = 9, Spearman r =-0.583,
p = 0.099). The difference between eNAA levels in the TBI patients
(median 11.3, interquartile range [IQR] 8.8-19.1lmol L-1) and
non-TBI patients (median 24.8, IQR 15.3-36.7lmol L-1) also was
not significant (Mann-Whitney, p = 0.113). However, a clear dif-
ference was observed between eNAA concentrations between non-
TBI and TBI patients at time-points 96 h+ post-injury (Fig. 4).
Relationship between NAA
and other microdialysis analytes
The concentrations of neurological analytes of clinical rele-
vance (glucose, pyruvate, lactate, glutamate, and glycerol) were
determined in the microdialysis fluid of the eight time-course
FIG. 3. The concentrations of extracellular N-acetylaspartate (eNAA) measured in microdialysates from 22 traumatic brain injury
(TBI) patients and six non-TBI patients plotted vs. time post-injury (TBI patients) or time post-operation (non-TBI patients). Of the 22
TBI patients, four received non-supplemented perfusion fluid, and 15 received perfusion fluid supplemented with 4 mM glucose. The
patient groups are differentiated by symbols as indicated: filled triangles, TBI patients without glucose; filled squares, TBI patients with
4 mM glucose; open circles, non-TBI patients with 4 mM glucose. Each data-point represents one 8 h pooled sample. There was a
significant inverse relationship for NAA vs. post-injury time for the group of 15 TBI patients receiving perfusion fluid supplemented
with 4 mM glucose (n= 30 data-points, Spearman r= -0.396, p = 0.030). Some of the 15 TBI patients with 4 mM glucose had more than
one pooled sample available, making 30 data-points for this group (as shown in Table 1). Color image is available online at
www.liebertpub.com/neu
FIG. 4. The extracellular N-acetylaspartate (eNAA) concentra-
tions in microdialysis samples from six non- traumatic brain in-
jury (TBI) patients vs. those measured in 30 non-TBI patients at
time-points taken after 96 h post-injury. The 30 TBI patients are
divided into two groups; the TBI patients of which four received
non-supplemented perfusion fluid and 15 received perfusion fluid
supplemented with 4 mM glucose, and the time-course TBI pa-
tients who received non-supplemented perfusion fluid. Graphs
were plotted from 24 h pooled samples for the non-TBI and TBI
patients (n= 6 and 22, respectively), and 8 h pooled samples from
the TBI time-course patients (n = 8). Color image is available
online at www.liebertpub.com/neu
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TBI patients alongside their eNAA levels. Figure 5 shows the
individual analyte and eNAA profiles of five of these patients
throughout the monitoring period. The data-points from all eight
patients were pooled for each of the analytes studied, and their
relationship with eNAA levels investigated. Bivariate scatter-
grams for the individual analytes are shown in Figure 6. A sig-
nificant inverse correlation was established between eNAA and
pyruvate (Fig. 6B), while there was a significant positive corre-
lation between eNAA and glycerol (Fig. 6E). There was also
a strong and significant positive linear relationship between
eNAA and the L/P ratio (Fig. 6C). It was noted that the highest
concentration of pyruvate and the highest L/P ratios were observed
FIG. 5. Illustrative examples of the temporal profile of extracellular N-acetylaspartate (eNAA; lM), plotted alongside the concen-
trations of pyruvate, glutamate and glycerol (in lM), glucose and lactate (in mM), and the lactate/pyruvate (L/P) ratio, all measured in
brain microdialysates. Extracellular NAA was quantified by high-performance liquid chromatography and the other analytes by ISCUS
analysis. These data are from Patients 1–5 of the time-course study. Concentrations are plotted vs. time post-injury. Each data-point
represents one 8 h pooled sample. Color image is available online at www.liebertpub.com/neu
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FIG. 6. Graphs illustrating the relationships between extracellular N-acetylaspartate (eNAA) concentrations and those of lactate (A),
pyruvate (B), the lactate/pyruvate (L/P) ratio (C), glutamate (D), glycerol (E) and glucose (F), all measured in microdialysates from the
eight time-course traumatic brain injury patients (pooled data). Extracellular NAA was quantified by high-performance liquid chro-
matography and the other analytes by ISCUS analysis. Each data-point represents one 8 h pooled sample. There was a significant inverse
correlation between eNAA and pyruvate (n = 57, Spearman r= -0.418, p = 0.001; Fig. 5B), a strong and significant positive linear
relationship (n = 57, Pearson r= 0.561, p< 0.00001) between eNAA and the L/P ratio (Fig. 5C), and a significant positive correlation
between eNAA and glycerol (n= 49, Spearman r = 0.360, p = 0.011; Fig. 5E).
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in Patient 2, in whom both these parameters showed a steady de-
crease throughout the monitoring period. This same patient was
seen as having the highest initial eNAA concentration of all the
patients studied, as well as notably the worst clinical outcome
(GOS score 2).
Discussion
This study has shown that elevated eNAA levels after TBI
correlate with adverse brain chemistry judged by conventional
microdialysis analytes, including the lactate/pyruvate ratio. Pre-
vious work on NAA has focused mainly on total tissue NAA
measured via scans (in patients), or in brain tissue extracts (from
animals). It is now well established that a transient decrease in brain
tissue NAA is not necessarily a signal of irreversible neuronal loss.
NAA loss in brain tissue appears reversible after less severe forms
of brain injury.24,31–33 Measuring and interpreting brain tissue
NAA by in vivo MRS is gaining ground as a useful non-invasive
tool in patient management applicable to both severe TBI patients
in parallel with invasive multimodality monitoring, as well as in
less severe injury. However, scans such as these are only snapshots
of the brain performed once or perhaps twice during a patient’s stay
in neurocritical care. Our aim in the present study has been to assess
eNAA concentrations post-TBI, and determine whether or not these
show a similar behavioral pattern to the total NAA measured by
scanning techniques in TBI patients, or in brain tissue extracts from
animal models. In addition to this, we aimed to ascertain the rela-
tionship, if any, between eNAA and established extracellular
markers of brain chemistry (namely glucose, lactate, pyruvate,
glutamate, glycerol, and the lactate/pyruvate ratio). The continuous
nature of microdialysis means that it can be applied to monitor
changes in brain energy metabolism after TBI, using time-variant
information that would not be available from single time-point
scans.
Mechanism of NAA efflux immediately after TBI
It is known that the concentration of NAA in extracellular fluid is
significantly lower than the tissue NAA concentration in the human
brain.34 Previous studies using 1H-MRS have reported whole–brain
NAA levels of approximately 12 mM.8,35,36 In the present study, we
have detected average NAA concentrations in the range of 10–
20 lM in extracellular fluid obtained from both injured and unin-
jured patients, suggesting a substantial NAA gradient from the
intracellular to the extracellular environment. Our time-course
analysis of eight patients following severe TBI by MD showed an
initial elevated level of eNAA in the first day after injury, after
which the concentration rapidly decreased from 24 to 75 h post-
injury before stabilizing (at *15lM) from 75 h post-injury until
monitoring ceased at around 120 h post-injury. Notably, the initial
steep decline in eNAA concentration did not occur in patients
where the MD catheter was inserted later and monitoring did not
begin until 50 h+ post-injury; in the latter patients, the decline over
time was considerably shallower. These results suggest that the
initial high eNAA concentration in the early time-points post injury
was mainly a result of the injury rather than as an artifact of catheter
insertion.
In animal models subjected to controlled TBI followed by in-
duced hypotension-hypoxia, Al Samsam and colleagues report an
eNAA concentration of approximately 10 lM before injury using a
microdialysis flow rate of 2 lL min-1.28 This eNAA concentration
subsequently increased to approximately 80lM at 100 min after
injury before steadily declining to *30 lM at the end of moni-
toring (240 min post-injury).28 Based on these results, Al Samsam
and colleagues suggest that at the time when monitoring ceased, the
eNAA concentration was in the process of returning to the initial
concentration measured prior to injury.28 Here, we have measured
eNAA in the parenchyma of eight non-TBI patients who have had a
microdialysis catheter inserted into radiographically normal brain
during resection surgery of benign brain tumors, enabling a com-
parison to be made between the extracellular environment of TBI
and non-TBI brain tissue. An average eNAA concentration of
26 lM was detected in the samples obtained from the non-TBI
subjects (24 h pooled microdialysates), which is higher than the
average of 17 lM obtained in TBI patients. The results obtained
here suggest that the steady-state eNAA concentration reached in
the days after severe TBI injury is lower than the baseline eNAA
level would have been before injury, which does not agree with the
theory of Al-Samsam and colleagues.27,28 This result is based on
the assumption that the non-TBI control patients used in this study
provided a true representation of healthy brain tissue.
Two mechanisms have been suggested for the increased efflux of
NAA from neurons into the extracellular environment in the first
few days after TBI. Firstly, direct mechanical injury caused by
insertion of the MD catheter could result in a concentrated area of
cellular damage. This would result in disruption of the plasma
membrane of neurons in the immediate area surrounding the probe,
releasing intracellular NAA into the tissue and causing a spike in
eNAA levels as previously shown in animal models.28,37 The return
to baseline levels after this kind of damage occurred £2 h after
insertion.28,37 The time-scale of re-equilibration after insertion of a
MD probe into human brain is not known but is likely to occur
within 3–4 h after insertion. As the monitoring of eNAA was per-
formed ‡12 h after MD probe insertion, we believe it is unlikely
that mechanical injury caused by MD probe insertion is the reason
for the high eNAA levels measured at earlier time-points in this
study. A more likely explanation for the elevated eNAA seen here
in the first 2 d after TBI is the release of intracellular neuronal NAA
into the extracellular environment. This efflux of intracellular NAA
could be the result of disruption of neuronal plasma membranes via
physical injury, or the intracellular acidosis and cellular swelling
commonly associated with ischemia, either of which would result
in the uncontrolled release of NAA.28,38,39 Alternatively, it has
been suggested that neurons could export NAA across the plasma
membrane via active transport.28
Reduced eNAA in later time-points after TBI
A decrease in the stabilized concentration of eNAA in the 50 h
after TBI, as observed here, has previously been reported in animal
models. Di Pietro and colleagues reported a decrease in eNAA in
the 6–12 h after severe TBI in rats, followed by stable eNAA levels
(*4–5 lmol g-1), which were 50% to 65% lower than the average
eNAA concentration in control (non-TBI) animals.6 This decrease
in the final concentration of eNAA >75 h after injury is similar
to the difference in eNAA levels we found in the present study
between the TBI patients at >96 h post-injury and the non-TBI
patients. Due to the lack of mortality in the small cohort of time-
course patients studied here, we were unable to draw conclusions as
to a possible difference in either the temporal profile or the actual
values of eNAA between surviving and non-surviving patients. We
also obtained no evidence to suggest that eNAA increased at later
time-points in patients with poor clinical outcome, as reported by
Belli and colleagues.23 It was noted that the concentration of eNAA
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was highest in the first sample taken after injury from the patient
with the worst clinical outcome. This result suggests the possibility
that higher eNAA concentrations immediately after injury (before
the ‘‘baseline’’ concentration is reached) could be associated with
poorer clinical outcome.
Several studies on whole–brain NAA levels measured by 1H-
MRS also have reported decreased NAA levels in TBI patients
>50 h after injury.40 A number of causal mechanisms have been
suggested; these include widespread neuronal loss resulting in a
concomitant reduction in the overall concentration of NAA present,
an increase in the uptake of eNAA by glial cells due to increasing
energy demands, and a decrease in the rate of NAA synthesis as a
result of mitochondrial or metabolic dysfunction.28,32,40 In this
study, we have attempted to establish the most probable of these
mechanisms by studying eNAA levels in response to the addition of
fuel (glucose) to the immediate extracellular environment, as well
as by establishing the temporal profiles of other biomarkers in re-
lation to eNAA in patients with TBI.
A link between ATP synthesis and the ability to synthesize NAA
was reported by Bates and colleagues,41 and a concomitant re-
duction in brain tissue NAA and ATP was found in animal models
of TBI and after mild TBI in humans.6,32,42 As much evidence
suggests that NAA is synthesized in the mitochondria, the NAA
depletion is thought to be a marker of metabolic impairment and the
depletion of energy stores in the brain.3,39,43 Moffet and col-
leagues39 propose that the decrease in NAA observed after brain
injury is partly the result of a reduction in synthesis due to a
shortage of acetyl-CoA brought about by metabolic crisis, as well
as increased degradation to provide acetate groups for lipid syn-
thesis in myelin repair, as described by Madhavaroe and col-
leagues.14 Under normal conditions, surplus acetyl-CoA not
required for ATP production via TCA cycle can be exported from
mitochondria to the cytoplasm if first converted to NAA by the
enzyme Asp-NAT. This cytoplasmic store of acetyl-CoA can then
be shuttled to oligodendrocytes, hydrolyzed by aspartoacylase, and
used for lipid synthesis and energy conversion.44 Under metabolic
stress, a shortage of acetyl-CoA could result in reduced NAA
synthesis and increased hydrolysis to provide acetate for myelin
repair.3,39 Among other functions ascribed to NAA is the idea that it
is involved in osmoregulation.16 Thus, release of intracellular NAA
into the extracellular space may be a response to hypo-osmotic
stress, although it is thought that NAA is only a minor contributor to
the pool of osmotically-active molecular species in brain.16
The synthesis of NAA is directly correlated to neuronal meta-
bolic state and the production of ATP. This has been confirmed by
Bates and colleagues, who showed that preventing ATP production
via the inhibition of enzymes of the oxidative phosphorylation
pathway also led to a decrease in NAA.41 Previous studies have
shown that artificially increasing the concentration of glucose in the
extracellular fluid leads to an improvement in neuronal energy
status (measured as ATP/adenosine diphosphate) after brain injury.6
Here we have measured eNAA levels in response to an increased
glucose concentration provided in the form of glucose-enriched
perfusion fluid (4 mM glucose) via the MD catheter. We show that
the average eNAA in TBI patients who received the glucose-
enriched perfusion fluid was not significantly different from that of
the TBI control patients (who received unsupplemented perfusion
fluid). A possible explanation is that the concentration of glucose
used, and the localized nature of MD-based perfusion, were insuf-
ficient to provide a definitive change in the metabolic state of the
surrounding neurons. This explanation appears consistent with the
ISCUS results for these patients during the unsupplemented and
glucose-supplemented periods, which showed an increase in mi-
crodialysate glucose concentration as expected but little change in
the levels of the other ISCUS analytes.30 Higher concentrations of
glucose, or administration over a larger area, may improve results
for this type of investigation. Another possible explanation could be
that the turnover of NAA is slow in brain tissue, as previously
suggested by labeling studies in animals.45
Relationship between eNAA and other MD analytes
The measurement of bioanalytes such as pyruvate, lactate, and
glucose using microdialysate analyzers can provide information
about the relative contributions of aerobic and anaerobic metabo-
lism, cell membrane integrity and the energy status of the brain.46
Elevated levels of lactate and a raised L/P ratio is indicative of
increased anaerobic metabolism, and acts as a reliable indicator of
ischemia or hypoxia, or mitochondrial dysfunction.30 Ischemia is
generally associated with poor outcomes in TBI patients, and can
occur as a result of increased ICP and inadequate levels of brain
oxygen or perfusion.46 With modern neurocritical care protocols,
ischemia usually is avoided, although microvascular ischemia may
occur in some cases.47 Glycerol, which is released by enzymatic
cleavage of cell membrane triglycerides, is regarded as an indicator
of tissue damage.48 In this study, a limited number of TBI patients
(n = 14) were monitored for brain oxygen (PbtO2) during the mi-
crodialysis sampling period. No relationship existed between
eNAA concentrations and average PbtO2 in this small dataset. All
of the average PbtO2 values measured were ‡20 mm Hg, except in
two patients whose average PbtO2 was in the high teens. None of
the TBI patients monitored had PbtO2 averages of £10 mm Hg,
indicating that none were badly hypoxic during monitoring.
Belli and colleagues have previously investigated the relation-
ship between eNAA and lactate, pyruvate, glycerol and glutamate
in 19 patients with TBI using MD.23 They report a non-recoverable
fall in NAA from Day 4 after injury onwards, which coincides with
increases in both the concentration of glycerol and the L/P ratio.23
Here, we established a significant correlation between eNAA and
glycerol, pyruvate, and L/P ratio in TBI patients, in agreement with
the relationships identified by Belli and colleagues.23 Overall, the
relationship between eNAA and pyruvate and the L/P ratio con-
firms the involvement of NAA in the energy state of neurons,
particularly in glycolysis and energy production within the cell, and
is consistent with the idea that eNAA increase is linked to adverse
brain metabolism. As glycerol is regarded as a marker of neuronal
membrane disintegrity, the observed correlation between eNAA
and glycerol suggests that the initial eNAA peak in the first 50 h
after injury may result from the release of intracellular NAA into
the interstitial space. The subsequent reduction in eNAA level at
>75 h after injury could therefore relate to a combination of neu-
ronal death and a reduced energy state in the remaining cells.
Limitations
The application of microdialysis for the sampling of bioanalytes
comes with the risk that an artificial signal could be generated by
localized injury sustained during catheter insertion into the tissue.
In this study, the monitoring of eNAA was performed ‡12 h after
catheter insertion to be certain that no such artifacts were analyzed.
As previously discussed, injury caused by probe insertion could
result in localized neuronal death and a spike of eNAA immediately
after catheter insertion.28,37 In the present study, we have concluded
that the initially high concentrations of eNAA detected in patients
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monitored at the earliest time-points were not an artifact associated
with catheter insertion, but rather the result of the TBI itself. This
conclusion was based on the results obtained from patients for
whom the monitoring began late (>50 h post-injury), where the
levels of eNAA measured were within the baseline range and did
not feature any significant variation. An additional limitation of the
microdialysis sampling technique used is that the measurement of
eNAA at time-points within 24 h of the time of injury, which would
be greatly informative for this particular study, is not possible due
to the time required for hospital admission and clinical treatment of
patients prior to catheter insertion. As with the earlier study by Belli
and colleagues,23 the small number of patients limits the present
study; also, the potential exists (at least in theory) for variations in
the microdialysis extraction efficiency for eNAA. However, be-
cause eNAA is a small water-soluble molecule (with a MW of
175 Da), recovery seems unlikely to be an issue. For future inves-
tigation, the analysis of eNAA by microdialysis sampling in com-
bination (within the same patients) with scans and spectroscopy
techniques such as 1H-MRS would certainly further the current
findings, and provide greater scope for determining the overall
function of NAA in the brain and its clinical implications.
Conclusions
In the present study, we have analyzed the temporal profile of
eNAA in eight patients with severe traumatic brain injury. We have
shown that the eNAA concentration decreases rapidly in the first
few days after injury, that a correlation exists between the level of
eNAA and time since injury, and that the stable eNAA concen-
trations following the initial decline were lower in subjects with
TBI than those measured in non-TBI patients. We additionally
show that eNAA concentrations showed a positive correlation with
glycerol and L/P ratio, and an inverse correlation with pyruvate. We
have additionally measured eNAA levels in 22 other TBI patients
and six tumor resection patients. We find no significant difference
between eNAA levels in patients who have received microdialysis
fluid supplemented with glucose and those who have not. Our
findings suggest that changes in eNAA after TBI are consistent with
adverse brain energy metabolism and the release of intracellular
components, perhaps as a result of neuronal death or injury. Re-
latively high levels of eNAA correlate with poor brain chemistry, as
determined using a conventional bedside microdialysis analyzer for
routine analytes, including the lactate/pyruvate ratio. Extracellular
NAA levels measured in microdialysates collected continuously at
the bedside provide extracellular information that is complemen-
tary to that of intermittent scans with in vivo MRS, in which di-
minished levels of (predominantly intracellular) total brain NAA is
regarded as indicative of adverse brain chemistry. Further research
is merited to ascertain whether elevated levels of eNAA are a useful
microdialysate biomarker of neuronal damage and disturbed me-
tabolism, with potential applicability to patient prognosis and to
monitoring of therapies. Currently, eNAA is only measurable off-
line in the laboratory, which limits its potential clinical utility, but
in principle, development of a specific sensor for bedside use may
be feasible in future.
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